000 02649cam a2200289zu 4500
001 88962931
003 FRCYB88962931
005 20250429180615.0
006 m o d
007 cr un
008 250429s2022 fr | o|||||0|0|||eng d
020 _a9780323853965
035 _aFRCYB88962931
040 _aFR-PaCSA
_ben
_c
_erda
100 1 _aK Danquah, Michael
245 0 1 _aEmerging Nanomedicines for Diabetes Mellitus Theranostics
_c['K Danquah, Michael', 'Jeevanandam, Jaison']
264 1 _bElsevier Science
_c2022
300 _a p.
336 _btxt
_2rdacontent
337 _bc
_2rdamdedia
338 _bc
_2rdacarrier
650 0 _a
700 0 _aK Danquah, Michael
700 0 _aJeevanandam, Jaison
856 4 0 _2Cyberlibris
_uhttps://international.scholarvox.com/netsen/book/88962931
_qtext/html
_a
520 _aEmerging Nanomedicines for Diabetes Mellitus Theranostics provides readers with information on the development of efficacious nanomedicines as potential theranostic agents for diabetes. The book discusses the application of various novel nanomaterials and nanocomposites for targeted delivery of insulin, glucose sensing, including nano-tattoos as glucose monitors, biosynthesized nanoparticles for diabetes treatment, and pre-clinical and clinical assays to evaluate the efficacy of nanomedicines for diabetes treatment. This is an important references source for materials scientists, pharmaceutical scientists and biomedical engineers who want to increase their understanding of how nanotechnology is being used to improve diabetes treatment. Diabetes has emerged as one of the most common diseases associated with lifestyle choices in the modern world, with significant mortality rates. Conventional treatment methods mainly involve insulin-based therapies. However, insulin therapy possesses several limitations such as weight gain and hypoglycemia. Thus, advanced research in nanomedicine is targeting the development of new and improved diagnostics and treatment methods for diabetes. - Explores the significance of nanomaterials and nanocomposites for the controlled delivery of insulin and effective diagnosis of diabetes - Assesses the efficacy of novel nano-tattoos as an emerging glucose monitoring system and the potential of biosynthesized nanoparticles as pharmaceutical ingredients for diabetes treatment - Describes various pre-clinical and clinical assays to evaluate the toxicity of nanomedicines, along with methods to mitigate the challenges associated with effective diabetes therapy via the use of nanorobots, nanoformulations and smartphone-based technologies
999 _c1322808
_d1322808